ARB204

ARB204 is a novel bispecific antibody targeting cadherin-17 (CDH17) and programmed cell death protein 1 (PD-1), developed by Arbele for the treatment of advanced gastrointestinal (GI) cancers. CDH17 is a cell adhesion molecule overexpressed in various GI malignancies, including gastric, colorectal, and pancreatic cancers, while showing restricted expression in healthy intestinal tissues. ARB204 is designed to simultaneously block the PD-1/PD-L1 immunosuppressive axis and redirect PD-1-expressing T cells to CDH17-positive tumor cells, thereby enhancing anti-tumor immunity while minimizing off-target toxicity. Preclinical studies have demonstrated that ARB204 effectively binds both targets and induces T-cell mediated killing of CDH17-positive cancer cells, such as the pancreatic AsPC1 cell line.